Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI
NCT05869162
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
153
Enrollment
OTHER
Sponsor class
Conditions
Non-small-cell Lung Carcinoma
Interventions
DRUG:
SY-3505
Sponsor
Shouyao Holdings (Beijing) Co. LTD